No abstract

Objective: To explore the prokinetic effect of Ranitidine, to compare it with the prokinetic effect of Neostigmineand to observe the potentiating prokinetic effect of Ranitidine and Neostigmine in combination. Study Design: Randomised controlled trial (experimental study). Place and Duration of Study: Multi disciplinary centre, Army Medical College, Rawalpindi, from Jan to Dec 2015. Methodology: Experiments were performed on three groups of rabbits (n=6) and Cumulative dose responsecurves were plotted using isolated duodenal tissue on power lab (USA). In the first two groups of experiments,cumulative concentrations of Neostigmine and Ranitidine were studied separately with neostigmine acting as acontrol and in the third group the potentiating effect of a fixed dose of ranitidine on neostigmine was evaluated. Results: Neostigmine’s response was taken as 100 percent and Ranitidine’s response when compared to it came out to be 197 percent. The dose response curve of Neostigmine was shifted to the left and upwards in the presence of Ranitidine. The percent response with Neostigmine alone was taken as 100 percent and increased to 212 percent when the tissue was pre-treated with Ranitidine. Conclusion: Our study has indicated that Ranitidine has marked prokinetic effect which is found to be greaterthan Neostigmine. It is also inferred that Ranitidine can potentiate the prokinetic effect of Neostigmine.

Introduction: Ranitidine is known to us all as an anti-ulcer drug which acts by blocking H 2 receptors in the stomach parietal cells. However its role in this category has been understated. We studied its prokinetic effect on isolated duodenum of rabbits and its synergistic interaction with Levosulpiride. The purpose of the study was to see if the two drugs do have a prokinetic effect and whether the combined effect is greater than the individual drugs. Study Design: Laboratory based Randomised controlled trial. Period: November 2014 to November 2015. Setting: The study was carried out in the multidisciplinary laboratory at Army Medical College after approval from Animals ethics committee. Material and methods: Dose response curve was constructed using cumulatively increasing concentrations of Ranitidine (Group 1) and Levosulpiride (Group 2). The synergistic prokinetic drug-drug interaction of Ranitidine and Levosulpiride was observed in Group 3 on iWorx Data acquisition unit (PowerLab). Results and Conclusion: Ranitidine produced a dose dependent reversible contraction of the isolated duodenum and the maximum effect was recorded at 35 µg as 0.136 mV. Levosulpiride produced a maximum contraction of 0.088 mV at 70 µg. Ranitidine and levosulpiride curve was shifted to the left and upwards of levosulpiride alone. The percent responses of levosulpiride alone was 90 percent and with ranitidine was 122 percent. Ranitidine and levosulpiride have a synergistic prokinetic interaction in vitro. Conclusion: Ranitidine and levosulpiride have a synergistic prokinetic drug-drug interaction in vitro.

Introduction: Ranitidine is known to us all as an anti-ulcer drug which acts byblocking H2 receptors in the stomach parietal cells. However its role in this category has beenunderstated. We studied its prokinetic effect on isolated duodenum of rabbits and its synergisticinteraction with Levosulpiride. The purpose of the study was to see if the two drugs do have aprokinetic effect and whether the combined effect is greater than the individual drugs. StudyDesign: Laboratory based Randomised controlled trial. Period: November 2014 to November2015. Setting: The study was carried out in the multidisciplinary laboratory at Army MedicalCollege after approval from Animals ethics committee. Material and methods: Dose responsecurve was constructed using cumulatively increasing concentrations of Ranitidine (Group 1)and Levosulpiride (Group 2). The synergistic prokinetic drug-drug interaction of Ranitidine andLevosulpiride was observed in Group 3 on iWorx Data acquisition unit (PowerLab). Resultsand Conclusion: Ranitidine produced a dose dependent reversible contraction of the isolatedduodenum and the maximum effect was recorded at 35 μg as 0.136 mV. Levosulpiride produceda maximum contraction of 0.088 mV at 70 μg. Ranitidine and levosulpiride curve was shifted tothe left and upwards of levosulpiride alone. The percent responses of levosulpiride alone was90 percent and with ranitidine was 122 percent. Ranitidine and levosulpiride have a synergisticprokinetic interaction in vitro. Conclusion: Ranitidine and levosulpiride have a synergisticprokinetic drug-drug interaction in vitro.